VCMCVC Market Cap
Menu

Resilience valuation, funding and investors

resilience.com ↗LinkedIn ↗

Resilience works in biologics manufacturing, based in Blue Ash, United States. Founded in 2020, it has about 1,310 employees.

Pharmaceutical Products Blue Ash Series D
VALUATION · TODAY
$3.27B −13% after Series D
Range $633M – $12.95B · Grade D
TODAY
+12 MO
$5.00B
$10.00B
$15.00B
2021
2022
2023
2024
2025
2026
2027
Series B $800M
Series C $600M
Series D $625M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY1,307 employees
+0%6m growth
−5%1y growth
−18%2y growth
1,000
2,000
Data from May 2022
TODAY
Predicted in 1 yr $2.85B −13% vs today
Predicted next raise $1.06B if a round comes
Winding-down probability 59%
Last round
Series D · $625M · Jun 2022
Valuation at last round
$7.55B · implied
Headcount
1,307 · flat
Grade
D
Founded
2020
How VCMC values companies →

Resilience valuation today

VCMC values Resilience at $3.3B today, with a range of $633M to $13.0B and a grade of D. The valuation starts from its last funding round, a Series D round in Jun 2022.

Valuation by date (86 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Resilience: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2020$15.3M$5.58M – $42.1M$17.1M (+11%)before first round–unknownD0%
1 Feb 2020$15.5M$5.63M – $42.5M$17.2M (+11%)before first round–unknownD0%
1 Mar 2020$15.6M$5.68M – $42.9M$17.4M (+11%)before first round–unknownD0%
1 Apr 2020$15.7M$5.73M – $43.3M$17.5M (+11%)before first round–unknownD0%
1 May 2020$15.9M$5.78M – $43.6M$17.7M (+11%)before first round–unknownD0%
1 Jun 2020$16.0M$5.84M – $44.0M$17.9M (+11%)before first round–unknownD0%
1 Jul 2020$16.2M$5.89M – $44.4M$18.0M (+11%)before first round–unknownD0%
1 Aug 2020$16.3M$5.94M – $44.8M$18.2M (+11%)before first round–unknownD0%
1 Sep 2020$16.5M$6.00M – $45.2M$18.3M (+11%)before first round–unknownD0%
1 Oct 2020$16.6M$6.05M – $45.6M$18.5M (+11%)before first round–unknownD0%
1 Nov 2020$16.8M$6.11M – $46.1M$18.7M (+11%)before first round–unknownD0%
24 Nov 2020$5.7B$3.8B – $13.0B$8.6B (+50%)after a round–unknownC0%
1 Dec 2020$5.8B$3.8B – $13.0B$8.6B (+49%)after a round–unknownC0%
1 Jan 2021$6.0B$3.8B – $13.0B$8.6B (+44%)after a round–unknownC0%
1 Feb 2021$6.2B$3.8B – $13.0B$8.6B (+39%)after a round–unknownC0%
1 Mar 2021$6.4B$3.8B – $13.0B$8.6B (+35%)after a round–unknownC0%
1 Apr 2021$6.6B$3.8B – $13.0B$8.6B (+30%)after a round–unknownC0%
1 May 2021$6.8B$3.8B – $13.0B$8.6B (+26%)after a round–unknownC0%
1 Jun 2021$7.1B$3.8B – $13.0B$8.6B (+21%)after a round–unknownC0%
1 Jul 2021$7.3B$3.8B – $13.0B$8.6B (+17%)after a round–unknownC0%
1 Aug 2021$5.5B$3.6B – $10.8B$7.1B (+30%)after a round–unknownB0%
2 Aug 2021$5.5B$3.6B – $10.8B$7.1B (+30%)after a round–unknownB0%
1 Sep 2021$5.6B$3.6B – $10.8B$7.1B (+27%)after a round–unknownB0%
1 Oct 2021$5.7B$3.6B – $10.8B$7.1B (+24%)after a round–unknownB0%
1 Nov 2021$5.8B$3.6B – $10.8B$7.1B (+22%)after a round–unknownB0%
1 Dec 2021$6.0B$3.6B – $10.8B$7.1B (+19%)after a round–unknownB0%
1 Jan 2022$6.1B$3.6B – $10.8B$7.1B (+16%)after a round–unknownB0%
1 Feb 2022$6.2B$3.6B – $10.8B$7.1B (+14%)after a round–unknownB0%
1 Mar 2022$6.4B$3.6B – $10.8B$7.1B (+12%)after a round–unknownB0%
1 Apr 2022$6.5B$3.6B – $10.8B$7.1B (+9%)after a round–unknownB0%
1 May 2022$6.6B$3.6B – $10.8B$7.1B (+7%)after a round1,400unknownB0%
1 Jun 2022$6.8B$3.6B – $10.8B$7.1B (+4%)after a round1,400unknownB0%
7 Jun 2022$7.6B$5.3B – $13.9B$9.8B (+30%)after a round1,400unknownB0%
1 Jul 2022$7.7B$5.3B – $13.9B$9.8B (+28%)after a round1,400unknownB0%
1 Aug 2022$7.9B$5.3B – $13.9B$9.8B (+25%)after a round1,400unknownB0%
1 Sep 2022$8.0B$5.3B – $13.9B$9.8B (+22%)after a round1,400unknownB0%
1 Oct 2022$8.2B$5.3B – $13.9B$9.8B (+20%)after a round1,400unknownB0%
1 Nov 2022$8.4B$5.3B – $13.9B$9.8B (+17%)after a round1,400unknownB0%
1 Dec 2022$8.6B$5.3B – $13.9B$9.8B (+14%)after a round1,400unknownB0%
1 Jan 2023$8.8B$5.3B – $13.9B$9.8B (+12%)after a round1,400unknownB0%
1 Feb 2023$9.0B$5.3B – $13.9B$9.8B (+9%)after a round1,400unknownB0%
1 Mar 2023$9.1B$5.3B – $13.9B$9.8B (+7%)after a round1,400unknownB0%
1 Apr 2023$9.4B$5.3B – $13.9B$9.8B (+5%)after a round1,400unknownB0%
1 May 2023$10.0B$5.6B – $14.7B$10.4B (+3%)after a round1,800upB0%
1 Jun 2023$10.3B$5.6B – $14.7B$10.4B (0%)after a round1,800upB0%
1 Jul 2023$10.4B$5.6B – $14.7B$10.4B (0%)after a round1,800upB0%
1 Aug 2023$10.4B$5.5B – $14.7B$10.4B (0%)after a round1,800upB0%
1 Sep 2023$10.4B$5.4B – $14.7B$10.4B (0%)after a round1,800upB0%
1 Oct 2023$10.4B$5.4B – $14.7B$10.4B (0%)after a round1,800upB0%
1 Nov 2023$10.4B$4.5B – $14.7B$10.4B (0%)after a round1,800flatB0%
1 Dec 2023$10.4B$4.3B – $14.7B$10.4B (0%)after a round1,800flatC0%
1 Jan 2024$10.4B$4.1B – $14.7B$10.4B (0%)after a round1,800flatC0%
1 Feb 2024$10.4B$3.9B – $14.7B$10.4B (0%)after a round1,800flatC0%
1 Mar 2024$10.4B$3.8B – $14.7B$10.4B (0%)after a round1,800flatC0%
1 Apr 2024$9.4B$3.5B – $14.1B$8.8B (-6%)after a round1,700flatC18%
1 May 2024$9.3B$3.4B – $14.1B$8.8B (-6%)after a round1,700flatC18%
1 Jun 2024$9.3B$3.2B – $14.2B$8.7B (-6%)after a round1,700flatC18%
1 Jul 2024$9.2B$2.9B – $14.2B$8.5B (-8%)after a round1,700flatC18%
1 Aug 2024$7.3B$2.7B – $13.5B$5.8B (-21%)after a round1,600downC53%
1 Sep 2024$7.2B$2.6B – $13.6B$5.7B (-21%)after a round1,600downC53%
1 Oct 2024$7.1B$2.5B – $13.7B$5.5B (-22%)after a round1,600downC53%
1 Nov 2024$6.7B$2.4B – $13.7B$5.0B (-25%)after a round1,600downC60%
1 Dec 2024$6.2B$2.2B – $13.7B$4.4B (-28%)after a round1,600downC70%
1 Jan 2025$6.0B$2.1B – $13.8B$4.3B (-29%)after a round1,600downC70%
1 Feb 2025$5.9B$2.0B – $13.9B$4.2B (-30%)after a round1,600downC70%
1 Mar 2025$5.8B$1.9B – $14.0B$4.1B (-30%)after a round1,600downC70%
1 Apr 2025$5.7B$1.8B – $14.1B$4.0B (-31%)after a round1,600downD70%
1 May 2025$5.9B$1.7B – $14.2B$4.2B (-30%)after a round1,600downD65%
1 Jun 2025$6.1B$1.7B – $14.3B$4.3B (-29%)after a round1,600downD59%
1 Jul 2025$5.8B$1.6B – $14.3B$4.3B (-26%)after a round1,600downD55%
1 Aug 2025$3.6B$1.5B – $14.0B$2.3B (-37%)after a round1,418downD97%
1 Sep 2025$3.5B$1.4B – $13.9B$2.2B (-37%)after a round1,380downD97%
1 Oct 2025$3.7B$1.3B – $13.8B$2.4B (-36%)after a round1,380downD89%
1 Nov 2025$3.4B$1.2B – $13.7B$2.1B (-37%)after a round1,336downD93%
1 Dec 2025$3.3B$1.2B – $13.7B$2.1B (-37%)after a round1,336downD93%
1 Jan 2026$3.0B$1.1B – $13.7B$1.9B (-38%)after a round1,297downD97%
1 Feb 2026$2.9B$1.1B – $13.7B$1.8B (-38%)after a round1,297downD97%
1 Mar 2026$2.8B$1.0B – $13.7B$1.8B (-38%)after a round1,297downD97%
1 Apr 2026$2.7B$964M – $13.7B$1.7B (-38%)after a round1,302downD97%
1 May 2026$2.7B$918M – $13.7B$1.7B (-37%)after a round1,303downD97%
1 Jun 2026$2.8B$872M – $13.6B$1.9B (-33%)after a round1,303flatD89%
1 Jul 2026$2.8B$830M – $13.4B$2.1B (-25%)after a round1,303flatD82%
1 Aug 2026$3.0B$789M – $13.3B$2.4B (-21%)after a round1,303flatD76%
1 Sep 2026$3.2B$750M – $13.2B$2.6B (-19%)after a round1,303flatD70%
1 Oct 2026$3.4B$714M – $13.1B$2.8B (-16%)after a round1,307flatD64%
24 Oct 2026$3.3B$633M – $13.0B$2.8B (-13%)after a round1,307flatD59%

Key facts about Resilience

Founded
2020
Headquarters
Blue Ash, United States
Employees
about 1,310 -2% in a year
Total raised
$2.02B
Funding rounds
3
Last round
Series D Jun 2022

Resilience was founded in 2020 by Patrick Y. Yang, Rahul Singhvi, Robert Nelsen and Sandy Mahatme.

Resilience funding history

Resilience has 3 funding rounds on record, from Nov 2020 to Jun 2022, $2.02B in total. None disclosed a valuation.

  1. Series D 6 Jun 2022

    Investors not disclosed.

    Sources: finsmes.com, resilience.com, genengnews.com and 2 more

    $625M

  2. Series C 1 Aug 2021

    Investors not disclosed.

    Sources: finsmes.com, resilience.com, bioprocessintl.com and 1 more

    $600M

  3. Series B 23 Nov 2020

    Led by ARCH Venture Partners, 8VC; with GV, New Enterprise Associates.

    Sources: resilience.com, techcrunch.com, globalgenes.org and 2 more

    $800M

Resilience investors

4 investors have backed Resilience; 8VC and ARCH Venture Partners led at least one round.

What Resilience does

Resilience works in pharmaceutical products, with 15 recorded offerings and customers in pharmaceuticals and biotechnology.

National Resilience, LLC is an American contract development and manufacturing organization engaged in biomanufacturing for complex medicines. The company provides services in biologics manufacturing, cell therapy development, gene therapy manufacturing, nucleic acid manufacturing, and vaccine manufacturing. Resilience also offers integrated formulation and fill/finish capabilities, as well as digital twin-based process optimization. Its operations are supported by a global supply chain and logistics network, and the company is certified for regulatory compliance and quality standards.

Description from Veridion's company data.

Products and services

  • Biologics Manufacturing
  • Cell Therapy Development
  • Gene Therapy Manufacturing
  • Nucleic Acid Manufacturing
  • Vaccine Manufacturing
  • Aseptic Drug Product Manufacturing
  • Drug Substance Manufacturing
  • Formulation and Fill-Finish Services
  • Digital Twin Technology Integration
  • Single-Use Process Line Implementation
  • Regulatory Compliance Consulting
  • Complex Medicine Development Services
  • Complex Medicine Commercialization Services
  • Strategic Partnership Development
  • Sustainable Manufacturing Solutions

Markets

  • Pharmaceuticals
  • Biotechnology

Technology

  • Digital Twins
  • Single-Use Process Lines
  • Integrated Formulation and Fill/Finish Capabilities

Business model

  • Business-to-Business
  • Service Provider
  • Manufacturing
  • Enterprise

Industry codes (NAICS)

  • 325414 Biological Product (except Diagnostic) Manufacturing 100% match

Questions about Resilience

What is Resilience worth?

Valuation $3.3B (range $633M to $13.0B), as of 24 Oct 2026.

Has Resilience raised money?

Resilience has 3 funding rounds on record, from Nov 2020 to Jun 2022, $2.02B in total. None disclosed a valuation.

Who has invested in Resilience?

8VC, ARCH Venture Partners, GV and New Enterprise Associates. Lead investors include 8VC and ARCH Venture Partners.

How many people work at Resilience?

About 1,310, down 2% over the last year. Headcount rose from 1,400 in Apr 2022 to 1,800 in Apr 2023, then fell to 1,307 in Sep 2026.

What does Resilience do?

Resilience works in pharmaceutical products, with 15 recorded offerings and customers in pharmaceuticals and biotechnology. Its main offerings are biologics manufacturing, cell therapy development and gene therapy manufacturing.

When was Resilience founded, and where is it based?

Resilience was founded in 2020 and is based in Blue Ash, United States. It has about 1,310 employees, down 2% over the last year.

How we value companiesReport an issue